(Q54578867)

English

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Myoung Joo Kang

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Yong Sang Hong

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Kyu-pyo Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Sun Young Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Ji Yeon Baek

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Min-Hee Ryu

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Jae-Lyun Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Heung Moon Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Mi-Jung Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Hee Jin Chang

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Yoon-Koo Kang

11

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Tae Won Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

publication date

25 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

30

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

1607-1613

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

https://scigraph.springernature.com/pub.10.1007/s10637-011-9703-8

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Monoclonal antibodies in cancer therapy: 25 years of progress

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9703-8

21 January 2018

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9703-8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21706149

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54578867&oldid=1566601026"